Scroll

dobutamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics	937	34368-04-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dobutamine dobutamine hydrochloride dobutamine HCl	A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY. Molecular weight: 301.39 Formula: C18H23NO3 CLOGP: 2.43 LIPINSKI: 0 HAC: 4 HDO: 4 TPSA: 72.72 ALOGS: -4.34 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dobutamine
dobutamine hydrochloride
dobutamine HCl

A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.

Molecular weight: 301.39
Formula: C18H23NO3
CLOGP: 2.43
LIPINSKI: 0
HAC: 4
HDO: 4
TPSA: 72.72
ALOGS: -4.34
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.50	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.13 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance)	115 mL/min/kg	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 18, 1978	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Stress cardiomyopathy	175.58	27.54	50	3705	9400	63475867
Cardiogenic shock	140.19	27.54	49	3706	17883	63467384
Drug ineffective	96.91	27.54	198	3557	1044567	62440700
Multiple organ dysfunction syndrome	83.32	27.54	48	3707	56704	63428563
Cardiac failure	63.54	27.54	48	3707	89094	63396173
Toxic epidermal necrolysis	55.57	27.54	28	3727	25306	63459961
Vasoplegia syndrome	55.24	27.54	14	3741	1685	63483582
Local anaesthetic systemic toxicity	53.10	27.54	12	3743	887	63484380
Septic shock	45.51	27.54	35	3720	66594	63418673
Drug ineffective for unapproved indication	45.17	27.54	27	3728	34036	63451231
Pulmonary hypertension	43.03	27.54	27	3728	37096	63448171
Ventricular tachycardia	40.66	27.54	21	3734	19958	63465309
Cardiac arrest	37.41	27.54	36	3719	92509	63392758
Ureaplasma infection	34.74	27.54	8	3747	643	63484624
Status epilepticus	33.87	27.54	17	3738	15216	63470051
Renal failure	31.91	27.54	37	3718	117615	63367652
Ventricular fibrillation	31.66	27.54	15	3740	11852	63473415
Stevens-Johnson syndrome	31.07	27.54	19	3736	24931	63460336
Pulmonary arterial hypertension	30.19	27.54	18	3737	22559	63462708
Fatigue	29.73	27.54	8	3747	888020	62597247
Renal impairment	29.51	27.54	31	3724	88324	63396943
Respiratory failure	29.25	27.54	33	3722	101825	63383442

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	523.48	31.00	150	6844	8451	34941486
Appendicitis	451.12	31.00	152	6842	14655	34935282
Multiple organ dysfunction syndrome	403.52	31.00	227	6767	76339	34873598
Stress	394.44	31.00	167	6827	30180	34919757
Ventricular fibrillation	313.69	31.00	131	6863	22823	34927114
Ascites	303.02	31.00	159	6835	46412	34903525
Abdominal distension	258.64	31.00	155	6839	58337	34891600
Blood phosphorus increased	225.94	31.00	77	6917	7644	34942293
Hyponatraemia	207.47	31.00	154	6840	82537	34867400
General physical health deterioration	178.59	31.00	170	6824	128099	34821838
Sepsis	174.08	31.00	189	6805	166372	34783565
Constipation	136.92	31.00	152	6842	136830	34813107
Abdominal pain	118.26	31.00	154	6840	163464	34786473
Dry mouth	112.84	31.00	72	6922	30093	34919844
Myasthenia gravis	99.30	31.00	41	6953	6899	34943038
Blood uric acid increased	98.87	31.00	45	6949	9579	34940358
Off label use	88.37	31.00	231	6763	419293	34530644
Vomiting	76.82	31.00	159	6835	247462	34702475
Toxic epidermal necrolysis	71.93	31.00	48	6946	21598	34928339
Drug ineffective	67.68	31.00	222	6772	456529	34493408
Stress cardiomyopathy	65.96	31.00	22	6972	2037	34947900
Hyperphosphataemia	59.38	31.00	25	6969	4412	34945525
Fatigue	58.83	31.00	4	6990	370649	34579288
Condition aggravated	57.82	31.00	122	6872	192074	34757863
Blood cholesterol increased	57.51	31.00	41	6953	20502	34929435
Analgesic therapy	54.36	31.00	16	6978	982	34948955
Drug therapy	52.24	31.00	16	6978	1125	34948812
Incorrect route of product administration	51.92	31.00	34	6960	14811	34935126
Cardiogenic shock	50.16	31.00	42	6952	26576	34923361
Nausea	49.04	31.00	164	6830	339744	34610193
Platelet distribution width increased	48.53	31.00	10	6984	134	34949803
Sleep disorder therapy	45.37	31.00	14	6980	1009	34948928
Somnolence	43.63	31.00	79	6915	111037	34838900
Iron deficiency	42.49	31.00	21	6973	5360	34944577
Ventricular tachycardia	36.33	31.00	35	6959	26544	34923393
Neuralgia	33.00	31.00	26	6968	15087	34934850

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	583.80	25.15	149	10162	8402	79725675
Multiple organ dysfunction syndrome	468.23	25.15	252	10059	119994	79614083
Appendicitis	461.02	25.15	151	10160	20643	79713434
Ventricular fibrillation	372.57	25.15	144	10167	31782	79702295
Ascites	318.03	25.15	167	10144	75395	79658682
Stress	315.44	25.15	169	10142	79443	79654634
Blood phosphorus increased	248.91	25.15	80	10231	10267	79723810
Abdominal distension	237.36	25.15	163	10148	119487	79614590
Sepsis	209.05	25.15	213	10098	269215	79464862
Stress cardiomyopathy	207.25	25.15	71	10240	11095	79722982
Hyponatraemia	164.60	25.15	155	10156	177693	79556384
Cardiogenic shock	157.47	25.15	86	10225	41828	79692249
Drug ineffective	149.94	25.15	387	9924	1080526	78653551
General physical health deterioration	145.12	25.15	178	10133	275060	79459017
Constipation	119.37	25.15	164	10147	282886	79451191
Toxic epidermal necrolysis	108.25	25.15	69	10242	44512	79689565
Blood uric acid increased	103.52	25.15	45	10266	13315	79720762
Myasthenia gravis	100.54	25.15	41	10270	10358	79723719
Off label use	97.80	25.15	297	10014	906918	78827159
Fatigue	81.13	25.15	12	10299	929715	78804362
Abdominal pain	80.60	25.15	164	10147	389405	79344672
Dry mouth	72.38	25.15	72	10239	87947	79646130
Ventricular tachycardia	66.60	25.15	50	10261	41885	79692192
Hyperphosphataemia	61.15	25.15	25	10286	6351	79727726
Analgesic therapy	61.09	25.15	16	10295	993	79733084
Vasoplegia syndrome	59.31	25.15	21	10290	3609	79730468
Drug therapy	58.33	25.15	16	10295	1185	79732892
Condition aggravated	56.42	25.15	167	10144	500957	79233120
Platelet distribution width increased	52.82	25.15	10	10301	135	79733942
Sleep disorder therapy	51.40	25.15	14	10297	1010	79733067
Cardiac failure	46.90	25.15	77	10234	154765	79579312
Arthralgia	46.19	25.15	9	10302	571794	79162283
Right ventricular failure	44.08	25.15	31	10280	23466	79710611
Local anaesthetic systemic toxicity	41.88	25.15	12	10299	1042	79733035
Status epilepticus	40.06	25.15	30	10281	25011	79709066
Incorrect route of product administration	39.19	25.15	34	10277	34895	79699182
Iron deficiency	37.60	25.15	21	10290	10633	79723444
Drug ineffective for unapproved indication	36.81	25.15	39	10272	51199	79682878
Fall	36.67	25.15	9	10302	487620	79246457
Hypernatraemia	36.63	25.15	23	10288	14428	79719649
Vomiting	34.90	25.15	174	10137	665654	79068423
Renal injury	33.31	25.15	23	10288	16904	79717173
Low cardiac output syndrome	33.18	25.15	10	10301	1035	79733042
Dizziness	32.07	25.15	14	10297	526427	79207650
Eosinophilic myocarditis	31.64	25.15	10	10301	1212	79732865
Fear	30.06	25.15	24	10287	21962	79712115
Ventricular arrhythmia	30.05	25.15	17	10294	8823	79725254
Somnolence	30.04	25.15	83	10228	238898	79495179
Electrocardiogram ST segment elevation	28.14	25.15	16	10295	8381	79725696
Weight decreased	27.79	25.15	6	10305	355192	79378885
Asthenia	27.57	25.15	16	10295	511673	79222404
Renal impairment	27.40	25.15	62	10249	157721	79576356
Myoclonus	27.21	25.15	25	10286	27635	79706442
Cardiac arrest	27.02	25.15	65	10246	172031	79562046
Septic shock	26.83	25.15	53	10258	122748	79611329
Renal failure	26.45	25.15	71	10240	200897	79533180
Cardiomyopathy	26.37	25.15	25	10286	28749	79705328
Pulmonary alveolar haemorrhage	25.98	25.15	17	10294	11440	79722637

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01CA07	CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents
FDA MoA	N0000000245	Adrenergic beta-Agonists
FDA EPC	N0000175555	beta-Adrenergic Agonist
CHEBI has role	CHEBI:35522	beta-adrenergic agonists
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:38147	cardiotonic drugs
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D058665	Adrenergic beta-1 Receptor Agonists
MeSH PA	D000318	Adrenergic beta-Agonists
MeSH PA	D002316	Cardiotonic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D020011	Protective Agents
MeSH PA	D013566	Sympathomimetics

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Cardiogenic shock	indication	89138009
Decompensated cardiac failure	indication	195111005
Stress echocardiography using dobutamine	indication	703338002
Cardiac Decompensation	indication
Cardiac Decompensation Post Cardiac Surgery	indication
Organic Cardiac Disease	indication
Ventricular premature beats	contraindication	17338001
Myocardial infarction	contraindication	22298006	DOID:5844
Hypovolemia	contraindication	28560003
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypokalemia	contraindication	43339004
Atrial fibrillation	contraindication	49436004	DOID:0060224
Aortic valve stenosis	contraindication	60573004	DOID:1712
Idiopathic hypertrophic subaortic stenosis	contraindication	360465008

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.98	acidic
pKa2	10.59	acidic
pKa3	13.49	acidic
pKa4	9.03	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	AGONIST	EC50	5.50	WOMBAT-PK	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST	EC50	6.20	WOMBAT-PK	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	5.98	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.00	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6.42	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.87	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	5.77	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	6.91	DRUG MATRIX
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		Ki	6.32	CHEMBL
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.35	DRUG MATRIX
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN		Ki	5.72	CHEMBL
Carbonic anhydrase 4	Enzyme	P22748	CAH4_HUMAN		Ki	5.05	CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN		Ki	5.01	CHEMBL
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN		Ki	5.36	CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	5.26	DRUG MATRIX
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	6.14	CHEMBL
Carbonic anhydrase 5B, mitochondrial	Enzyme	Q9Y2D0	CAH5B_HUMAN		Ki	6.05	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	5.37	CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		IC50	5.26	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.40	DRUG MATRIX
Catechol O-methyltransferase	Enzyme	P21964	COMT_HUMAN		Km	4.30	WOMBAT-PK
Carbonic anhydrase 3	Enzyme	P07451	CAH3_HUMAN		Ki	5.13	CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN		Ki	5.02	CHEMBL
Carbonic anhydrase 14	Enzyme	Q9ULX7	CAH14_HUMAN		Ki	4.92	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	5.38	CHEMBL
Carbonic anhydrase 13	Enzyme	Q8N1Q1	CAH13_HUMAN		Ki	5.02	CHEMBL
Arachidonate 15-lipoxygenase	Enzyme		LOX15_RABIT		IC50	6.22	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	6.73	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	5.80	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	6.96	CHEMBL
Carbonic anhydrase 15	Enzyme		CAH15_MOUSE		Ki	6.41	CHEMBL

External reference:

ID	Source
4019730	VUID
N0000147822	NUI
D00632	KEGG_DRUG
49745-95-1	SECONDARY_CAS_RN
203121	RXNORM
4017541	VANDF
4019730	VANDF
C0012963	UMLSCUI
CHEBI:4670	CHEBI
Y00	PDB_CHEM_ID
CHEMBL926	ChEMBL_ID
DB00841	DRUGBANK_ID
CHEMBL1200418	ChEMBL_ID
D004280	MESH_DESCRIPTOR_UI
36811	PUBCHEM_CID
535	IUPHAR_LIGAND_ID
3340	INN_ID
3S12J47372	UNII
2871	MMSL
4625	MMSL
d00215	MMSL
000614	NDDF
000615	NDDF
26523005	SNOMEDCT_US
387145002	SNOMEDCT_US
90118002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9141	INJECTION, SOLUTION	12.50 mg	INTRAVENOUS	ANDA	20 sections
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1073	INJECTION	100 mg	INTRAVENOUS	NDA	18 sections
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1073	INJECTION	100 mg	INTRAVENOUS	NDA	18 sections
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1075	INJECTION	200 mg	INTRAVENOUS	NDA	18 sections
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1075	INJECTION	200 mg	INTRAVENOUS	NDA	18 sections
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1077	INJECTION	400 mg	INTRAVENOUS	NDA	18 sections
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1077	INJECTION	400 mg	INTRAVENOUS	NDA	18 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2344	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	21 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2344	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	21 sections
Dobutamine in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2346	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	12 sections
Dobutamine in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2347	INJECTION, SOLUTION	200 mg	INTRAVENOUS	NDA	12 sections
Dobutamine in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3724	INJECTION, SOLUTION	400 mg	INTRAVENOUS	NDA	12 sections
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	14335-171	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	21 sections
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	14335-172	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	21 sections
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4562	INJECTION	400 mg	INTRAVENOUS	NDA	18 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1330	INJECTION, SOLUTION	200 mg	INTRAVENOUS	NDA	12 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1330	INJECTION, SOLUTION	200 mg	INTRAVENOUS	NDA	12 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1337	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	12 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1337	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	12 sections
DOBUTAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1566	INJECTION	100 mg	INTRAVENOUS	NDA	11 sections
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5717	INJECTION, SOLUTION	12.50 mg	INTRAVENOUS	ANDA	11 sections
Dobutamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5777	INJECTION, SOLUTION	400 mg	INTRAVENOUS	NDA	12 sections
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	62778-350	INJECTION, SOLUTION	12.50 mg	INTRAVENOUS	ANDA	2 sections
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	70436-203	INJECTION	250 mg	INTRAVENOUS	ANDA	21 sections